miR-4461 inhibits the progression of Gallbladder carcinoma via regulating EGFR/AKT signaling

Cell Cycle. 2022 Jun;21(11):1166-1177. doi: 10.1080/15384101.2022.2042775. Epub 2022 Feb 23.

Abstract

Increasing evidence has demonstrated that microRNAs (miRNAs) participated in the tumorigenesis, progression and recurrence of various malignancies including Gallbladder carcinoma (GBC). miR-4461 was reported to work as a tumor suppressor gene in renal cell carcinoma. However, the role of miR-4461 in GBC remains unknown. Herein, we show that miR-4461 is downregulated in gallbladder cancer stem cells (CSCs). Forced miR-4461 expression attenuates the self-renewal, tumorigenicity of gallbladder CSCs, and inhibits proliferation and metastasis of GBC cells. Conversely, miR-4461 knockdown promotes the self-renewal of gallbladder CSCs, and facilities proliferation and metastasis of GBC cells. Mechanistically, miR-4461 inhibits GBC progression via downregulating EGFR/AKT pathway. Special EGFR siRNA or AKT overexpression virus abolishes the discrepancy of self-renewal, tumorigenesis, growth, and metastasis between miR-4461 overexpression GBC cells and their control cells. In conclusion, miR-4461 suppresses GBC cells self-renewal, tumorigenicity, proliferation, and metastasis by inactivating EGFR/AKT signaling, and may therefore prove to be a potential therapeutic target for GBC patients.

Keywords: AKT; EGFR; Gallbladder carcinoma; cancer stem cell; miR-4461.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Carcinogenesis / genetics
  • Cell Line, Tumor
  • Cell Proliferation / genetics
  • Cell Transformation, Neoplastic
  • ErbB Receptors / genetics
  • ErbB Receptors / metabolism
  • Gallbladder Neoplasms* / genetics
  • Gallbladder Neoplasms* / metabolism
  • Gallbladder Neoplasms* / pathology
  • Humans
  • MicroRNAs* / genetics
  • MicroRNAs* / metabolism
  • Proto-Oncogene Proteins c-akt* / metabolism

Substances

  • MIRN4461 microRNA, human
  • MicroRNAs
  • EGFR protein, human
  • ErbB Receptors
  • Proto-Oncogene Proteins c-akt

Grants and funding

This work was supported by the National Natural Science Foundation of China [81972777]; Natural Science Foundation of Shanghai [19ZR1400300].